Navigation Links
FDA Approves Viibryd to Treat Major Depressive Disorder
Date:1/21/2011

SILVER SPRING, Md., Jan. 21, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Viibryd tablets (vilazodone hydrochloride) to treat major depressive disorder in adults.  

(Logo:  http://photos.prnewswire.com/prnh/20090824/FDALOGO)

Major depressive disorder, also called major depression, is characterized by symptoms that interfere with a person's ability to work, sleep, study, eat, and enjoy once-pleasurable activities. Episodes of major depression often recur throughout a person's lifetime, although some may experience only a single occurrence.

Signs and symptoms of major depression include: depressed mood, loss of interest in usual activities, significant change in weight or appetite, insomnia or excessive sleeping (hypersomnia), restlessness/pacing (psychomotor agitation), increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and suicide attempts or thoughts of suicide. All people with major depression do not experience the same symptoms.

"Major depressive disorder is disabling and prevents a person from functioning normally," said Thomas Laughren, M.D., director of the Division of Psychiatry Products in the FDA's Center for Drug Evaluation and Research. "Medications affect everyone differently, so it is important to have a variety of treatment options available to patients who suffer from depression."

The most frequent adverse reactions reported by patients taking Viibryd in clinical trials included diarrhea, nausea, vomiting, and insomnia.

The drug will be available in 10, 20 and 40 milligram tablets.

Viibryd and all other antidepressant drugs have a boxed warning and a patient medication guide describing the increased risk of suicidal thinking and behavior in children, adolescents, and young adults ages 18 to 24 during initial treatment.

The warning
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... , March 31, 2015  CVS Health (NYSE: ... into new clinical affiliations with Rush University Medical ... and Tucson Medical Center in Tucson, ... Arizona Connected Care. These affiliations will help enhance ... patients. Through these clinical affiliations, CVS Health will ...
(Date:3/31/2015)... , March 31, 2015  Oxis International, Inc. (OXIS) ... development and commercialization, announced today Oxis CEO Tony ... of Oxis common shares on the Euronext exchange. Oxis ... the symbol OXIS.   Oxis Chairman and ... to move forward with its strategies launched in 2014 ...
(Date:3/31/2015)... MIAMI , March 31, 2015 ... TALOS™, today announced a strategic partnership with ... solutions for clinical research in life sciences. Offering ... global CRO has deployed Medidata,s electronic data capture ... support Biorasi,s Phase I through IV global clinical ...
Breaking Medicine Technology:CVS Health Announces New Clinical Affiliations with Leading Medical Centers in Arizona and Illinois 2CVS Health Announces New Clinical Affiliations with Leading Medical Centers in Arizona and Illinois 3Oxis International Inc. Announces Request for Euronext Trading Suspension 2Biorasi Selects Medidata's Cloud-Based Platform for Optimal Trial Operations 2Biorasi Selects Medidata's Cloud-Based Platform for Optimal Trial Operations 3Biorasi Selects Medidata's Cloud-Based Platform for Optimal Trial Operations 4
... 15, 2012 ViroPharma Incorporated,s (Nasdaq: VPHM ) ... expected to be released on Tuesday, February 28, 2012 before ... company will host a conference call and live audio webcast ... the conference call, ViroPharma management will discuss the 2011 fourth ...
... is a compelling example of the life-changing importance of organ ... decision to donate his wife,s organs in hopes of helping ... when he received a donor heart transplant after 120 days ... . (Photo: http://photos.prnewswire.com/prnh/20120215/LA53807 ) ...
Cached Medicine Technology:ViroPharma to Release 2011 Fourth Quarter and Full Year Financial Results on February 28, 2012 2Total Artificial Heart Patient Receives Donor Heart 15 Years After Decision to Donate Wife's Organs 2Total Artificial Heart Patient Receives Donor Heart 15 Years After Decision to Donate Wife's Organs 3Total Artificial Heart Patient Receives Donor Heart 15 Years After Decision to Donate Wife's Organs 4
(Date:3/31/2015)... (PRWEB) March 31, 2015 Karen A. ... 2015 at Rivier University’s Commencement ceremony on ... of humane letters in recognition of her eminent career ... Serving as a front-line caregiver and senior staff nurse ... years and advancing to leadership roles, including President of ...
(Date:3/31/2015)... (PRWEB) March 31, 2015 Indosoft, developer of ... Asterisk 1.4 support in development of their 5.x line. The ... Asterisk has been deployed around the world for more than ... 1.4 as a telephony platform, Q-Suite can fully embrace newer ... quality call center software on Asterisk for more than a ...
(Date:3/31/2015)... CA (PRWEB) March 31, 2015 ... joins BayBio’s Membership Program , the premiere ... the region’s 1300+ life science companies. , ... of the world’s most innovative and productive life ... to solve some of humanity’s most pressing challenges. ...
(Date:3/31/2015)... March 31, 2015 Healthpointe’s team of ... at all of their clinics. Specialties include hip dislocations, ... , For athletes with hip injuries, Healthpointe has a ... and treat the symptoms and underlying causes of the ... care and prevent future damage, while taking into consideration ...
(Date:3/31/2015)... OR (PRWEB) March 31, 2015 Former 49ers ... announcement than during his first year of a promising NFL ... Sports on Earth Senior Writer Will Leitch explores ... the league. Leitch talks about the decision making process that ... the preservation of health over a large paycheck, and what ...
Breaking Medicine News(10 mins):Health News:Rivier University to recognize nurse leader, educator and safety advocate at 80th Commencement on May 9th 2Health News:Rivier University to recognize nurse leader, educator and safety advocate at 80th Commencement on May 9th 3Health News:Indosoft Announces End of Life for Asterisk 1.4 Support in Q-Suite 5 Call Center Software 2Health News:Clinovo Joins BayBio Membership Program, The Leading Life Science Association in Northern California 2Health News:Healthpointe Now Treating Hip Dislocations, Hip Fractures, Hip Bursitis, and Hip Strains at Locations in Southern California 2Health News:Will Leitch and the Curious Case of Chris Borland on SCI TV 2Health News:Will Leitch and the Curious Case of Chris Borland on SCI TV 3
... THURSDAY, Dec. 23 (HealthDay News) -- Eating a vegetarian diet ... the blood and urine, says a small new study. ... -- which is found in dietary proteins and is a ... themselves of the mineral. In these patients, high levels of ...
... pathway known as Wnt, commonly activated in cancers, causes ... enzyme that is vital in degrading proteins, preventing the ... of many proteins within the cell, researchers at UCLA,s ... is important because sequestering the enzyme, Glycogen Synthase Kinase ...
... , WEDNESDAY, Dec. 22 (HealthDay News) -- Confronting the ... are unaware they are taking dummy pills, researchers found ... fake still reported significant symptom relief. In a ... a control group received no treatment while the other ...
... HealthDay Reporter , THURSDAY, Dec. 23 (HealthDay News) -- Liz Smith ... The first signs of arthritis in Emily, now 18, appeared when ... Burke, Va. "She slipped in a swimming pool and had a ... the beginning of all of it." For several months, the ...
... of vascular diseases may also contribute to the failure ... dialysis patients, according to a study appearing in an ... Society of Nephrology (JASN). "Our findings raise ... to the relatively poor outcomes regarding the function and ...
... Dec. 22 (HealthDay News) -- A gene mutation that ... glioblastoma brain cancer has been identified by researchers. ... -- contributes to tumor development, promotes resistance to treatment ... with glioblastoma, the most common and deadly type of ...
Cached Medicine News:Health News:Vegetarian Diet Cuts Kidney Patients' Levels of Toxic Phosphorus 2Health News:UCLA researchers uncover new cell biological mechanism that regulates protein stability in cells 2Health News:Placebos Work -- Even if Patients Are in on the Secret 2Health News:Placebos Work -- Even if Patients Are in on the Secret 3Health News:Lifetime of Arthritis Has Not Held Back Teen 2Health News:Lifetime of Arthritis Has Not Held Back Teen 3Health News:Why does dialysis fail? 2Health News:Gene Mutation Found in One of Four Cases of Deadly Brain Cancers 2
... vascular closure device quickly seals ... procedures, allowing for early ambulation ... creates a mechanical seal by ... bio-absorbable anchor and collagen sponge, ...
Terumo's Optitorque offers superior torque and precision control. It's patient-friendly, high torque design makes it the catheter of choice for demanding angiography....
Jography angiographic catheter has a new material combination, a patented angled weld, a flat wire braid design with a XXL lumen. It also has an atraumatic soft tip....
Femoral selective catheter. Catheter material used is polyurethane (TRICOR). Guidewire campatibility is 0.038". Packaging 5/Box....
Medicine Products: